Europe

Providing Vision and Experience to manage regulatory Submissions in Europe

Europe

The European Union represents an important marketing opportunity in terms of dimensions thanks to the existing common regulations among countries via the centralized procedures. The pharmaceutical regulation in this region is governed by supranational bodies, such as the EMA and its working parties and associate partner authorities.

To succeed in the approach to these entities, a correct designation of the product and a detailed strategy about the best way to contact, timings, meeting preparations, obtention of proper advice, management of CTAs, among others, are crucial to achieve an accelerated approval.

Europe Solutions

  • Assessment of specific local requirements for a Member State
  • Assessment of product potential designation according to fast-track possibilities
  • Evaluation of including your product in the Priority Medicines (PRIME) programme for potential accelerated assessment
  • Support in classifying your company as SME (Small Medium Enterprise) and applications of associated waivers and exemptions
  • Regulatory roadmaps, gap analysis and feasibility assessments, including analysis of development time and costs
  • Scientific Advice Meetings (SAs) according to the needs in each stage of development

Schedule a free meeting!

Discuss your case with our experts and receive a valuable feedback

Share

Why Asphalion?

With 20+ years track record in handling submissions, Asphalion provides reliable support for all type of regulatory procedures in Europe. We provide regulatory strategy to anticipate any potential hurdle, coordinate your submissions and liaise with European agencies until the approval of the Marketing Authorisation.

Main benefits

Asphalion has large experience in writing, submitting and updating  all types of technical dossiers specified for each product type including:

  • New Chemical Entities
  • APIs
  • Generics and Hybrids
  • OCT market
  • Orphan Drug Designations
  • Biologicals and biosimilars
  • Advanced Therapy Medicinal Products
  • Herbal Medicines
  • Homeopathic Medicinal Products
  • Veterinary Medicinal products
  • Medical devices
  • In-vitro diagnostics and drug-device combinations.
  • Cosmetics and food supplements

Furthermore, Asphalion has a proven track record and experience in following tracks, timings and standard formats in centralized submission procedures involving all intervenient regulatory entities.

Related Resources

Flyer ATMPs Asphalion

ATMPs

Scientific & Regulatory Affairs Support during development of ATMPs & Biologics

EU Pharmacovigilance local contact services

EU Pharmacovigilance local contact services

EU Pharmacovigilance local contact services case study. Small biopharmaceutical company with one
pharmaceutical product authorized through
a Decentralized Procedure in 10 European
countries.
The Client has all PV local activities
outsourced to different vendors in each
country, which poses several challenges.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Related News & Events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review progress and shape the next

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting